Advances in therapy.2016，Vol.33Issue(10) ：17.DOI:10.1007/s12325-016-0396-4

Simple Predictive Model for Identifying Patients with Chronic Hepatitis C and Hepatitis C Virus Genotype 4 Infection with a High Probability of Sustained Virologic Response with Peginterferon Alfa-2a/Ribavirin: Pooled Analysis of Data from Two Large, International Cohort Studies

Asselah, Tarik Esmat, Gamal Sanai, Faisal M. Goulis, Ioannis Messinger, Diethelm Bakalos, Georgios Waked, Imam
Advances in therapy.2016，Vol.33Issue(10) ：17.DOI:10.1007/s12325-016-0396-4
✕
  • NSTL
  • Springer Nature

Simple Predictive Model for Identifying Patients with Chronic Hepatitis C and Hepatitis C Virus Genotype 4 Infection with a High Probability of Sustained Virologic Response with Peginterferon Alfa-2a/Ribavirin: Pooled Analysis of Data from Two Large, International Cohort Studies

Asselah, Tarik 1Esmat, Gamal 2Sanai, Faisal M. 3Goulis, Ioannis 4Messinger, Diethelm 5Bakalos, Georgios 6Waked, Imam7
扫码查看

作者信息

  • 1. Univ Paris Diderot, Hop Beaujon, AP HP, CRI,INSERM,UMR 1149,Serv Hepatol, 100 Bd Gen Leclerc, F
  • 2. Cairo Univ, Endem Med Dept, Cairo, Egypt
  • 3. King Saud Univ, Liver Dis Res Ctr, Riyadh, Saudi Arabia
  • 4. Aristotle Univ Thessaloniki, Sch Med, Hippokrat Gen Hosp, Dept Internal Med 4, Thessaloniki, Greece
  • 5. PROMETRIS GmbH, Mannheim, Germany
  • 6. F Hoffmann La Roche Ltd, Basel, Switzerland
  • 7. Natl Liver Inst, Shibin Al Kawm, Egypt
  • 折叠

Abstract

Wherever access to direct-acting antiviral agents is restricted, dual peginterferon/ribavirin (PegIFN/RBV) therapy remains an option for treatment of hepatitis C virus (HCV) genotype 4 (GT4) infection, which predominates in the Middle East and Sub-Saharan Africa. Our goal was to develop a baseline scoring system to identify GT4-infected patients with a low or high probability of achieving a sustained virologic response (SVR) with PegIFN alfa-2a/RBV using data from two large cohort studies.

Key words

Access to treatment/Genotype 4/HCV/Hepatology/Infectious diseases/Peginterferon alfa/Predictors/Ribavirin/Sustained virologic response

引用本文复制引用

出版年

2016
Advances in therapy.

Advances in therapy.

ISSN：0741-238X
被引量2
参考文献量38
段落导航相关论文